375 Participants Needed

Shingles for Vascular Dementia Risk

(R01 Trial)

Recruiting at 1 trial location
SP
Do
Overseen ByDirector of Research
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Center for Clinical Studies, Texas
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether individuals with shingles (herpes zoster) face a higher risk of blood vessel problems and mental decline compared to those without shingles. Participants will join either a group with untreated shingles, visiting the clinic multiple times over a year, or a control group with a single clinic visit. The trial involves no new medications or devices, only regular care and observations. Individuals with a current shingles rash who have not taken antiviral treatment and can commit to several follow-up visits may be suitable for this study. As an unphased trial, this study offers a unique opportunity to contribute to understanding the broader impacts of shingles on health.

Why are researchers excited about this trial?

Unlike the standard treatments for vascular dementia, which typically focus on managing symptoms like memory loss and confusion, this study is exploring how pathogenic exosomes linked to herpes zoster might increase the risk of developing the condition. Researchers are excited because understanding these tiny vesicles could reveal a completely new mechanism of disease progression, offering insights into how vascular dementia develops at a molecular level. This could eventually lead to innovative treatments that target the root cause rather than just alleviating symptoms, potentially altering the disease course and improving outcomes for patients.

Who Is on the Research Team?

PD

Project Director

Principal Investigator

University of Colorado, Denver

Are You a Good Fit for This Trial?

Inclusion Criteria

I am visiting the clinic for a skin check, with or without a rash.
I can attend all study visits and communicate with the study team.
I can sign a consent form for the study.
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Observation

Participants are evaluated for exosome content and vascular risk factors over a 12-month period

12 months
6 visits for HZ group, 1 visit for control group

Follow-up

Participants are monitored for long-term vascular and cognitive outcomes

12 months

What Are the Treatments Tested in This Trial?

Find a Clinic Near You

Who Is Running the Clinical Trial?

Center for Clinical Studies, Texas

Lead Sponsor

Trials
3
Recruited
190+

National Institute on Aging (NIA)

Collaborator

Trials
1,841
Recruited
28,150,000+